Government-Owned Inventions; Availability for Licensing, 69541-69542 [2016-24134]

Download as PDF Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Drug Discovery and Mechanisms of Antimicrobial Resistance. Date: November 3, 2016. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton McLean Tysons Corner, 7920 Jones Branch Drive, McLean, VA 22102. Contact Person: John C. Pugh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7808, Bethesda, MD 20892, (301) 435– 2398, pughjohn@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: September 30, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24126 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases: Notice of Closed Meeting sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Lasker Clinical Research Scholars Program (Si2/R00). Date: November 1, 2016. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: James T. Snyder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities/ Room 3G31B National Institutes of Health, NIAID, 5601 Fishers Lane MSC 9823, VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 69541 Rockville, MD 20892, (240) 669–5060, james.snyder@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 30, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. AGENCY: [FR Doc. 2016–24129 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases: Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Consortium for Food Allergy Research: Clinical Research Units (UM1). Date: November 16–18, 2016. Time: 7:30 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: The William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854. Contact Person: Louis A. Rosenthal, Ph.D., Scientific Review Officer Scientific Review Program, Division of Extramural Activities, Rm 3G42B National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC–79823 Bethesda, MD 20892–9823, (240) 669–5070, rosenthalla@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 30, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24130 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. Technology description follows. Use of Roseomonas species to treat eczematous (atopic dermatitis) skin disease Description of Technology: Atopic dermatitis, also known as eczema, is a chronic itchy skin disease that affects over 20% of infants and young children in industrialized nations and may persist into adulthood for up to 50% of these cases, making it one of the most common skin diseases in the US and other developed countries. Scientists at NIAID have developed a method of treating or preventing atopic dermatitis via the topical application of selected probiotic strains of gramnegative Roseomonas mucosa bacteria. This approach avoids the exhausting treatment demands of standard therapies and has been shown to be beneficial in a preclinical mouse model of atopic dermatitis. Potential Commercial Applications: • Treatment of eczema Competitive Advantages: • May be formulated as a cream or ointment SUMMARY: E:\FR\FM\06OCN1.SGM 06OCN1 69542 Federal Register / Vol. 81, No. 194 / Thursday, October 6, 2016 / Notices • Corticosteroid-free • Animal data available Development Stage: • In vivo data available (animal) Inventors: Ian A. Myles, Sandip Kumar Datta, all of NIAID. Publications: Myles IA, et al. Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight, 2016, Jul 7; 1(10). [PMID 27478874]. Intellectual Property: HHS Reference No. E–099–2016/0—US Patent Application No. 62/324,762 filed April 19, Year 2016. Licensing Contact: Dr. David Yang, 240–627–3413; polung.yang@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of Roseomonas species to treat eczematous (atopic dermatitis) skin disease. For collaboration opportunities, please contact Dr. David Yang, 240–627–3413; polung.yang@nih.gov. Dated: Septenber 30, 2016. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2016–24134 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health sradovich on DSK3GMQ082PROD with NOTICES National Institute on Aging: Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel Second Stage P01 Review. Date: November 21, 2016. Time: 8:00 a.m. to 5:00 p.m. VerDate Sep<11>2014 18:46 Oct 05, 2016 Jkt 241001 Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD 20817. Contact Person: Ramesh Vemuri, Ph.D., Chief, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2W200, Bethesda, MD 20892, 301–402–7700, rv23r@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: September 30, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24128 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the Board of Scientific Counselors for Basic Sciences, National Cancer Institute and the Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute. The meetings will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors for Basic Sciences, National Cancer Institute. Date: November 14, 2016. Time: 9:00 a.m. to 2:30 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, 31 Center Drive, Building 31, C-Wing, 6th Floor, Conference Room 6, Bethesda, MD 20892. Contact Person: Mehrdad Tondravi, Ph.D., Chief, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W302, Rockville, MD 20850, 240–276–5660, tondravim@mail.nih.gov. PO 00000 Frm 00034 Fmt 4703 Sfmt 9990 Name of Committee: Board of Scientific Counselors for Basic Sciences, National Cancer Institute. Date: November 14, 2016. Time: 6:00 p.m. to 9:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Hyatt Regency, 1 Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Mehrdad Tondravi, Ph.D., Chief, Institute Review Office, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W302, Rockville, MD 20850, 240–276–5660, tondravim@mail.nih.gov. Name of Committee: Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute. Date: November 14, 2016. Time: 6:00 p.m. to 9:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Hyatt Regency, 1 Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Brian E. Wojcik, Ph.D., Executive Secretary, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W414, Rockville, MD 20850, 240–276–5660, wojcikb@mail.nih.gov. Name of Committee: Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute. Date: November 15, 2016. Time: 8:30 a.m. to 2:45 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, 31 Center Drive, Building 31, C-Wing, 6th Floor, Conference Room 6, Bethesda, MD 20892. Contact Person: Brian E. Wojcik, Ph.D., Executive Secretary, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W414, Rockville, MD 20850, 240–276–5665, wojcikb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: September 30, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24127 Filed 10–5–16; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\06OCN1.SGM 06OCN1

Agencies

[Federal Register Volume 81, Number 194 (Thursday, October 6, 2016)]
[Notices]
[Pages 69541-69542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24134]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent application listed below may be obtained by 
communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: The invention listed below is owned by an 
agency of the U.S. Government and is available for licensing in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing. Technology description follows.
    Use of Roseomonas species to treat eczematous (atopic dermatitis) 
skin disease Description of Technology:
    Atopic dermatitis, also known as eczema, is a chronic itchy skin 
disease that affects over 20% of infants and young children in 
industrialized nations and may persist into adulthood for up to 50% of 
these cases, making it one of the most common skin diseases in the US 
and other developed countries.
    Scientists at NIAID have developed a method of treating or 
preventing atopic dermatitis via the topical application of selected 
probiotic strains of gram-negative Roseomonas mucosa bacteria. This 
approach avoids the exhausting treatment demands of standard therapies 
and has been shown to be beneficial in a preclinical mouse model of 
atopic dermatitis.
    Potential Commercial Applications:

 Treatment of eczema

    Competitive Advantages:

 May be formulated as a cream or ointment

[[Page 69542]]

 Corticosteroid-free
 Animal data available

    Development Stage:

 In vivo data available (animal)

    Inventors: Ian A. Myles, Sandip Kumar Datta, all of NIAID.
    Publications: Myles IA, et al. Transplantation of human skin 
microbiota in models of atopic dermatitis. JCI Insight, 2016, Jul 7; 
1(10). [PMID 27478874].
    Intellectual Property: HHS Reference No. E-099-2016/0--US Patent 
Application No. 62/324,762 filed April 19, Year 2016.
    Licensing Contact: Dr. David Yang, 240-627-3413; 
polung.yang@nih.gov. Collaborative Research Opportunity: The National 
Institute of Allergy and Infectious Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize the use of 
Roseomonas species to treat eczematous (atopic dermatitis) skin 
disease. For collaboration opportunities, please contact Dr. David 
Yang, 240-627-3413; polung.yang@nih.gov.

    Dated: Septenber 30, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-24134 Filed 10-5-16; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.